http://www.novonordisk.com/press/se...fdf-9187-43a53b21f3e8&sShowLanguageCode=en-GB
Lisbon, Portugal – Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes even when doses were given once-daily up to 40 hours apart, according to data presented today at the European Association for the Study of Diabetes (EASD) in Lisbon. Insulin degludec is still under clinical investigation and regulatory submission has not been filed.
Lisbon, Portugal – Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes even when doses were given once-daily up to 40 hours apart, according to data presented today at the European Association for the Study of Diabetes (EASD) in Lisbon. Insulin degludec is still under clinical investigation and regulatory submission has not been filed.
